IRIS Accounts Production v26.1.10.61 15316256 director 1.1.25 31.12.25 31.12.25 false true false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 15316256 2024-12-31 15316256 2025-12-31 15316256 2025-01-01 2025-12-31 15316256 2023-11-28 15316256 2023-11-29 2024-12-31 15316256 2024-12-31 15316256 ns15:EnglandWales 2025-01-01 2025-12-31 15316256 ns14:PoundSterling 2025-01-01 2025-12-31 15316256 ns10:Director1 2025-01-01 2025-12-31 15316256 ns10:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 15316256 ns10:SmallEntities 2025-01-01 2025-12-31 15316256 ns10:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 15316256 ns10:SmallCompaniesRegimeForDirectorsReport 2025-01-01 2025-12-31 15316256 ns10:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 15316256 ns10:FullAccounts 2025-01-01 2025-12-31 15316256 ns10:CompanySecretary1 2025-01-01 2025-12-31 15316256 ns10:RegisteredOffice 2025-01-01 2025-12-31 15316256 ns5:CurrentFinancialInstruments 2025-12-31 15316256 ns5:CurrentFinancialInstruments 2024-12-31 15316256 ns5:ShareCapital 2025-12-31 15316256 ns5:ShareCapital 2024-12-31 15316256 ns5:RetainedEarningsAccumulatedLosses 2025-12-31 15316256 ns5:RetainedEarningsAccumulatedLosses 2024-12-31 15316256 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-12-31 15316256 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-12-31

REGISTERED NUMBER: 15316256 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 December 2025

for

Venipharm Ltd

Venipharm Ltd (Registered number: 15316256)

Contents of the Financial Statements

for the Year Ended 31 December 2025

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 4 |

Venipharm Ltd

Company Information

for the Year Ended 31 December 2025

| DIRECTOR: | E Mauger

| SECRETARY: | Pramex International Ltd

| REGISTERED OFFICE: | 8th Floor South

| 11 Old Jewry

| London

| EC2R 8DU

| REGISTERED NUMBER: | 15316256 (England and Wales)

Venipharm Ltd (Registered number: 15316256)

Balance Sheet

31 December 2025

31.12.25 | 31.12.24 |

| Notes | £ | £

CURRENT ASSETS

Debtors | 4 | 468,712 |  | 166,073 |  |

Cash at bank | 75,593 |  | 128,159 |  |

544,305 |  | 294,232 |  |

CREDITORS

Amounts falling due within one year | 5 | 495,370 |  | 282,430 |  |

NET CURRENT ASSETS | 48,935 |  | 11,802 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 48,935 |  | 11,802 |  |

CAPITAL AND RESERVES

Called up share capital | 10,000 |  | 10,000 |  |

Retained earnings | 38,935 |  | 1,802 |  |

SHAREHOLDERS' FUNDS | 48,935 |  | 11,802 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Venipharm Ltd (Registered number: 15316256)

Balance Sheet - continued

31 December 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 25 June 2026 and were signed by:

E Mauger - Director

Venipharm Ltd (Registered number: 15316256)

Notes to the Financial Statements

for the Year Ended 31 December 2025

1. | STATUTORY INFORMATION

| Venipharm Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Amount are rounded to the nearest £.

| Going concern

| The company is dependent upon the continued financial support of its parent company

| which has undertaken to financially support the company for the at least 12 months after the

| date of the signing of these accounts and for the foreseeable future.

| The financial statements have therefore been prepared on a going concern basis.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Hire purchase and leasing commitments

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 1 (2024 - 1 ) .

Venipharm Ltd (Registered number: 15316256)

Notes to the Financial Statements - continued

for the Year Ended 31 December 2025

4. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

31.12.25 | 31.12.24 |

| £ | £

| Trade debtors | 82,962 |  | - |  |

| Amounts owed by group undertakings | 306,152 |  | 155,482 |  |

| Other debtors | 79,598 |  | 10,591 |  |

468,712 |  | 166,073 |  |

5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

31.12.25 | 31.12.24 |

| £ | £

| Trade creditors | 36,347 |  | 13,745 |  |

| Amounts owed to group undertakings | 409,506 |  | 242,023 |  |

| Taxation and social security | 12,732 |  | 927 |  |

| Other creditors | 36,785 |  | 25,735 |  |

495,370 |  | 282,430 |  |

6. | RELATED PARTY DISCLOSURES

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland, not to disclose related party transactions with wholly owned subsidiaries within the group.

7. | ULTIMATE CONTROLLING PARTY

| The immediate parent undertaking is Calonne SAS, a company registered in France. The

| address of its registered office is 4 Bureaux de la colline, Saint cloud, France, 92210.